Becton, Dickinson and Company currently draws coverage from 12 analysts who maintain a consensus "buy" rating on the medical technology giant. As of the data window ending June 25, 2026, the stock trades at $147.77, positioning it against a mean price target of $177.75. This gap represents an implied upside of 20.3%, a figure that captures the current disparity between market valuation and the street's long-term outlook. Investors monitoring the firm's trajectory should note that while the forward price-to-earnings ratio sits at a modest 11.04, the trailing P/E remains significantly higher at 25.79, highlighting a sharp contrast in how valuation models are currently pricing the company's future earnings power.
What analysts show
The recent revisions to price targets for BDX indicate a period of recalibration rather than consensus sentiment. While Barclays moved to increase its target to $204 in mid-May and Wells Fargo followed with a bump to $161, TD Cowen opted to lower its target to $163 during the same month. These shifts (occurring within the span of just one week) reflect a lack of unified momentum among top-tier firms. Furthermore, while there has been no meaningful insider buying activity recently, the data shows 10 instances of significant insider selling, totaling 6,875 shares. Whether this selling activity signals internal caution or simply routine liquidity management is a common point of debate for those tracking the Healthcare sector page for institutional shifts. With a low beta of 0.278, the stock is clearly behaving as a defensive anchor, which may explain why analysts remain attached to a "buy" rating despite the conflicting target adjustments.
Sector context
When placed against the broader landscape, BDX ranks 16th in terms of upside potential within its peer group. The stock’s 20.3% upside sits slightly below the healthcare sector average of 22.2%, suggesting that while BDX is priced for moderate growth, it is not currently the highest-conviction play compared to more aggressive peers. For instance, Boston Scientific (BSX) currently carries an implied upside of 73.3%, which dwarfs the projections assigned to BDX. Even Zoetis (ZTS) and Intuitive Surgical (ISRG) offer significantly higher upside potential at 59.4% and 40.6% respectively (each outperforming the BDX mean target by a wide margin). This relative positioning suggests that the street views BDX as a stable, lower-volatility asset, particularly when compared to the high-growth components of the medical device industry that continue to capture more bullish target price estimates from analysts.